Nurix Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>NT</div>
NRIX -- USA Stock  

USD 28.27  0.05  0.18%

It appears Nurix Therapeutics may not recover as fast as we have hopped for as its price went down 11.37% today. Nurix Therapeutics's current daily volatility is 7.99 percent, with a beta of -0.23 and an alpha of 1.48 over DOW. As some investors are moving away from the current market volatility rise, we are going to break down Nurix Therapeutics based on how it reacts to economic swings. We will analyze why it could be a much better year for Nurix Therapeutics shareholders.
Published over three weeks ago
View all stories for Nurix Therapeutics | View All Stories
Should you take in Nurix after the current volatility slide?
Nurix Therapeutics currently holds about 173.5 M in cash with 50.17 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.25. Nurix Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.2277, which conveys not very significant fluctuations relative to the market. Let's try to break down what Nurix's beta means in this case. As returns on the market increase, returns on owning Nurix Therapeutics are expected to decrease at a much lower rate. During the bear market, Nurix Therapeutics is likely to outperform the market. Although it is vital to follow Nurix Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. Our philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Nurix Therapeutics expected return of 1.29 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Nurix Therapeutics total risk alpha, downside variance, as well as the relationship between the Downside Variance and daily balance of power to analyze future returns on Nurix Therapeutics.
Investing in Nurix Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Nurix Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Nurix Therapeutics's Liquidity

Nurix Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Nurix Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Nurix Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Nurix Therapeutics's total debt and its cash.

How Nurix utilizes its cash?

To perform a cash flow analysis of Nurix Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nurix Therapeutics is receiving and how much cash it distributes out in a given period. The Nurix Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Nurix Therapeutics Correlation with Peers

Investors in Nurix can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Nurix Therapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Nurix Therapeutics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Nurix is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Nurix for more details

Acquisition by Sands Arthur T of 804170 shares of Nurix Therapeutics subject to Rule 16b-3

Legal trades by Nurix Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Nurix insider trading alert for grant of stock option (right to buy) by Sands Arthur T, President CEO, on 23rd of October 2020. This event was filed by Nurix Therapeutics Inc with SEC on 2020-10-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Details

Nurix Therapeutics is somewhat reliable given 1 month investment horizon. Nurix Therapeutics has Sharpe Ratio of 0.16, which conveys that the firm had 0.16% of return per unit of risk over the last month. Our standpoint towards estimating the risk of a stock is to use both market data as well as company specific technical data. We have analyzed and interpolated twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.29% are justified by taking the suggested risk. Use Nurix Therapeutics Risk Adjusted Performance of 0.1953, downside deviation of 5.73, and Mean Deviation of 5.38 to evaluate company specific risk that cannot be diversified away.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Nurix Therapeutics bad stories are not so bad

Nurix Therapeutics current standard deviation rises over 7.98. Nurix Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Nurix Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Nurix Therapeutics volatility.

Our Final Takeaway

While some firms in the biotechnology industry are either recovering or due for a correction, Nurix Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 1st of October 2020, we believe Nurix Therapeutics is currently fairly valued. It almost neglects market trends and projects average probability of distress in the next two years. Our final 30 days advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Nurix Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com